BioNTech Faces Class Action Lawsuit Over COVID-19 Vaccine Demand and Misleading Statements

A class action lawsuit has been filed against BioNTech SE and certain officers, alleging violations of federal securities laws. The lawsuit seeks to recover damages on behalf of investors who purchased BioNTech securities between March 30, 2022, and October 13, 2023. The complaint alleges that BioNTech overstated demand for its COVID-19 vaccine and made misleading statements about the product's relevance and in-demand status. The deadline for investors to request appointment as lead plaintiff is March 12, 2024.